Particle.news
Download on the App Store

Virtual Reality Test Predicts Short-Term Brain Shrinkage in Healthy Adults

A VR path-integration task tied to blood biomarkers may flag preclinical neurodegenerative risk.

Overview

  • A peer-reviewed study led by researchers at Fujita Health University found that poorer performance on an immersive virtual-reality path-integration (VR-PI) task at baseline predicted greater cortical thinning and regional brain volume loss about one year later.
  • The study followed 71 cognitively unimpaired adults, using high-resolution MRI and blood tests, and linked larger VR-PI distance and angular errors to tissue loss in regions vulnerable in early Alzheimer’s disease such as the parahippocampal gyrus and posterior cingulate cortex.
  • Baseline navigation errors were also associated with higher plasma p-tau181, a marker of tau pathology, and with elevated GFAP, a marker of astrocyte activation, tying the behavioral test to molecular signs of neurodegeneration.
  • VR-PI distance error accurately identified individuals who experienced the fastest regional decline, especially in the parahippocampal region, suggesting the test could help stratify short-term risk in otherwise healthy adults.
  • Authors and coverage stress this is an initial proof of concept from a modest, ~1-year study and say larger, longer and more diverse studies are required before the VR test can be used for clinical screening or monitoring.